SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Featured Reports
Apr 28, 2021
Mar 12, 2021

Press Releases

10 Jan
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
Leveraging Ginkgo’s high throughput screening and cell engineering capabilities and Selecta’s ImmTOR platform to advance gene therapy delivery with the goal of improved transduction, enhanced tissue tropism and reduced immunogenicity WATERTOWN, Mass. and BOSTON , Jan.
05 Jan
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
WATERTOWN, Mass. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
29 Dec
Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event
WATERTOWN, Mass. , Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
01 Dec
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
-DISSOLVE program on track with 12-month study fully enrolled- -DISSOLVE II on track for full enrollment in early 2022- -Top-line data from Phase 3 DISSOLVE program expected in H2 2022- WATERTOWN, Mass. and STOCKHOLM, Sweden , Dec. 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.